STOCK TITAN

Serina Therapeutics, Inc. - $ser STOCK NEWS

Welcome to our dedicated page for Serina Therapeutics news (Ticker: $ser), a resource for investors and traders seeking the latest updates and insights on Serina Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Serina Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Serina Therapeutics's position in the market.

Rhea-AI Summary
Serina Therapeutics appoints Dr. Simba Gill as Executive Chairman, bringing extensive leadership experience in transformative biotechnology platforms and drug development. Dr. Gill will lead the company forward in advancing its proprietary POZ PlatformTM drug delivery technology across various therapeutic modalities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.64%
Tags
management
-
Rhea-AI Summary
Serina Therapeutics completes merger with AgeX Therapeutics, to trade on NYSE American as 'SER' starting March 27, 2024. Lead candidate SER-252 progressing towards Phase I clinical trials for Parkinson's Disease treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.98%
Tags
Serina Therapeutics, Inc.

NYSE:SER

SER Rankings

SER Stock Data

23.48M
2.50M
Pharmaceutical Preparations
United States of America
ALAMEDA